# Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

> **NCT00771927** · — · COMPLETED · sponsor: **UCB Pharma** · enrollment: 1005 (actual)

## Conditions studied

- Epilepsies, Partial

## Interventions

- **DRUG:** Lacosamide

## Key facts

- **NCT ID:** NCT00771927
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 1005 (ACTUAL)
- **Last updated:** 2014-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00771927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00771927, "Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00771927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*